Skip to content
Catalyst

PapersPMID:22864465

A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

The American journal of psychiatry2012The record ↗

  1. Finding, moderate evidenceraisesDepression remission rate

What moved

1 findingHow to read these marks →
  • Increases depression remission rate

    moderate

    “The remission rate at end point was higher in the creatine group than in the placebo group (odds ratio=6.92, SE=5.07, p=0.008) (online supplemental Figure SF2).”
    Study
    RCT
    Duration
    8 weeks
    Effect
    6.92 odds ratio
    Dose studied
    creatine monohydrate 3 g/day for the first week, then 5 g/day for 7 weeks, added to escitalopram
    Population
    Women aged 19-65 with major depressive disorder, a current major depressive episode and a 17-item HAM-D score of 16 or greater; escitalopram (10 mg/day for week 1, then 20 mg/day, adjustable) given to both arms

Study record

Design
randomised controlled trial
Species
human
Population
women with major depressive disorder, creatine monohydrate (CHEBI:16919) augmentation of escitalopram
Participants
52
Comparator
placebo
Duration
56 days
Endpoints measured
32